Literature DB >> 34919223

NCAPG is a prognostic biomarker associated with vascular invasion in hepatocellular carcinoma.

Z-Y Guo1, Z-T Zhu.   

Abstract

OBJECTIVE: Vascular invasion is closely associated with tumor recurrence and poor patient outcomes in individuals diagnosed with hepatocellular carcinoma (HCC). In this study, we explored the potential value of NCAPG as a prognostic biomarker of vascular invasion in HCC patients.
MATERIALS AND METHODS: Two Gene Expression Omnibus (GEO) datasets (GSE14520 - GPL3721 Subset; GSE67140 - GPL8786) were utilized to explore the relationship between genes and HCC-associated vascular invasion. Hub genes associated with vascular invasion were identified through analyses of Cytoscape using the Cytohubba plugin, and relationships between specific genes and patient survival outcomes were assessed through univariate and multivariate analyses of the TCGA-Liver Hepatocellular Carcinoma (TCGA-LIHC) database.
RESULTS: In total, 10 hub genes were associated with vascular invasion in the two analyzed GEO datasets. Importantly, non-SMC condensin I complex subunit G (NCAPG) overexpression was correlated with poor prognosis for patients in the TCGA-LIHC database. NCAPG was identified as an independent predictor of HCC patient overall survival (OS) (HR 2.543; 95% CI 1.224, 5.285; p = 0.012) and disease-free survival (DFS) (HR 2.034; 95% CI 1.160, 3.566; p = 0.013) in a multivariate Cox analysis. NCAPG expression status, vascular invasion status, tumor status, and AJCC T stage were independent predictors of OS, with a concordance index (c-index) value of 0.713 (95% CI, 0.671, 0.756). NCAPG expression levels were related to hypomethylation status and were positively correlated with tumor immune cell infiltration and immune cell-related biomarker expression.
CONCLUSIONS: NCAPG upregulation is associated with poor prognosis in hepatocellular carcinoma patients with vascular invasion.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34919223     DOI: 10.26355/eurrev_202112_27417

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  3 in total

1.  Identification and Validation of a Potential Stemness-Associated Biomarker in Hepatocellular Carcinoma.

Authors:  Yangyang Zhang; Ruike Zhang; Lingxiu Zeng; Haizhou Wang; Ruyi Peng; Meng Zhang; Hailin Zhang; Zhenwei Yang; Liping Gao; Meng Wang; Jing Liu
Journal:  Stem Cells Int       Date:  2022-07-11       Impact factor: 5.131

2.  Identifying potential prognosis markers in hepatocellular carcinoma via integrated bioinformatics analysis and biological experiments.

Authors:  Xueting Hu; Jian Zhou; Yan Zhang; Yindi Zeng; Guitao Jie; Sheng Wang; Aixiang Yang; Menghui Zhang
Journal:  Front Genet       Date:  2022-07-19       Impact factor: 4.772

3.  Multi-omics data integration for hepatocellular carcinoma subtyping with multi-kernel learning.

Authors:  Jiaying Wang; Yuting Miao; Lingmei Li; Yongqing Wu; Yan Ren; Yuehua Cui; Hongyan Cao
Journal:  Front Genet       Date:  2022-09-06       Impact factor: 4.772

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.